Dengue Fever
Conditions
Keywords
Dengue Vaccine, Dengue Virus, Dengue Hemorrhagic Fever, Dengue Shock Syndrome
Brief summary
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.
Detailed description
More than 2 billion people living in tropical and subtropical regions of the world are at risk of dengue virus infection. Dengue viruses cause dengue fever, as well as the more severe dengue hemorrhagic fever/shock syndrome, and dengue virus infection is the leading cause of hospitalization and death in children in several tropical Asian countries. This study will evaluate the safety and immunogenicity of a live, attenuated dengue virus called rDEN1delta30, which is derived from the Western Pacific DEN1 serotype. This study will last 180 days. Participants in Cohort 1 will be randomly assigned to receive rDEN1delta30 or placebo at study entry. Cohort 2 will begin only after safety review of all participants in Cohort 1. Participants in Cohort 2 will receive a higher dose of rDEN1delta30 or placebo. After vaccination, participants will be asked to monitor their temperature every day for 16 days. Study visits will occur every other day after vaccination until Day 16, followed by 4 additional visits at selected days through Day 180. Blood collection and a targeted physical exam will occur at each study visit. Some participants will be asked to undergo a skin biopsy or additional blood collection at selected visits.
Interventions
BIOLOGICALrDEN1delta30
Live attenuated rDEN1delta30 vaccine
BIOLOGICALPlacebo
Placebo for rDEN1delta30
Sponsors
Johns Hopkins Bloomberg School of Public Health
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Willing to be followed for the duration of the study * Willing to use acceptable methods of contraception * Good general health
Exclusion criteria
* Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease * Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study * Liver, renal, or hematologic disease * Alcohol or drug abuse within 12 months of study entry * History of severe allergic reaction or anaphylaxis * Emergency room visit or hospitalization for severe asthma within 6 months of study entry * HIV-1 infected * HCV infected * Hepatitis B surface antigen positive * Known immunodeficiency syndrome * Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical or nasal corticosteroids are not excluded. * Live vaccine within 4 weeks of study entry * Killed vaccine within 2 weeks of study entry * Blood products within 6 months of study entry * Investigational drugs or vaccines within 60 days prior to study entry or while currently enrolled in this clinical trial * Previously received a licensed or experimental yellow fever or dengue vaccine * Surgical removal of spleen * History of dengue virus infection or other flavivirus infection * Other condition that, in the opinion of the investigator, would affect the participant's participation in the study * Pregnancy or breastfeeding * Plan to travel to an area where dengue infection is common
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the frequency of vaccine related AEs for each dose graded by severity | Throughout study |
| Determine the amount of dengue 1 neutralizing antibody induced by the vaccine | At Day 42 |
Secondary
| Measure | Time frame |
|---|---|
| To compare the T cell mediated immune response against dengue viruses of those volunteers infected with the rDEN1delta30 vaccine virus with that of uninfected volunteers and placebo recipients | Throughout study |
| To assess the durability of the antibody response | At Day 180 |
| To evaluate the immunopathological mechanism of vaccine-associated rash in those volunteers who are willing to undergo skin biopsy | Throughout study |
| If both doses of vaccine are administered, to compare the infectivity rates, safety, and immunogenicity between dose groups | At study completion |
| To assess the frequency, quantity, and duration of viremia in each dose cohort studied | Throughout study |
Countries
United States
Outcome results
None listed